Novan Inc
F:6LUA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
S
|
Sovereign Metals Ltd
LSE:SVML
|
AU |
|
Tsukui Staff Corp
TSE:7045
|
JP |
|
Dingdong (Cayman) Ltd
NYSE:DDL
|
CN |
|
A
|
aXichem AB (publ)
STO:AXIC A
|
SE |
|
Fukuoka REIT Corp
TSE:8968
|
JP |
|
A
|
ASBISc Enterprises PLC
WSE:ASB
|
CY |
Novan Inc
Other Long-Term Assets
Novan Inc
Other Long-Term Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Long-Term Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Novan Inc
F:6LUA
|
Other Long-Term Assets
$793k
|
CAGR 3-Years
-6%
|
CAGR 5-Years
0%
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Other Long-Term Assets
$19.3B
|
CAGR 3-Years
4%
|
CAGR 5-Years
9%
|
CAGR 10-Years
7%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Other Long-Term Assets
$8.2B
|
CAGR 3-Years
42%
|
CAGR 5-Years
20%
|
CAGR 10-Years
8%
|
|
|
Pfizer Inc
NYSE:PFE
|
Other Long-Term Assets
$19.3B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
28%
|
CAGR 10-Years
14%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Other Long-Term Assets
$17.8B
|
CAGR 3-Years
30%
|
CAGR 5-Years
13%
|
CAGR 10-Years
11%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Other Long-Term Assets
$17B
|
CAGR 3-Years
33%
|
CAGR 5-Years
22%
|
CAGR 10-Years
23%
|
|
Novan Inc
Glance View
Novan, Inc. is a biotechnology company, which engages in leveraging nitric oxide’s natural antiviral and immunomodulatory mechanisms of action to treat dermatological and oncovirus-mediated diseases. The company is headquartered in Durham, North Carolina and currently employs 29 full-time employees. The company went IPO on 2016-09-21. The firm is engaged in researching, developing and marketing products for skin diseases. The firm is focused on dermatology and anti-infective therapies. Its technology platform leverages nitric oxide’s naturally occurring anti-viral, anti-bacterial, anti-fungal, and immunomodulatory mechanisms of action to treat a range of diseases. The firm has clinical-stage dermatology and anti-infective drug candidates with multi-factorial (SB204), anti-viral (SB206), anti-fungal (SB208), and anti-inflammatory (SB414) mechanisms of action. The Company’s lead product candidate is SB206, which is a topical gel with anti-viral properties for the treatment of viral skin infections, with focus on molluscum contagiosum. The firm is exploring the potential of its NITRICIL technology as a potential treatment option for COVID-19, targeting the reduction of viral shedding and transmission.
See Also
What is Novan Inc's Other Long-Term Assets?
Other Long-Term Assets
793k
USD
Based on the financial report for Dec 31, 2022, Novan Inc's Other Long-Term Assets amounts to 793k USD.
What is Novan Inc's Other Long-Term Assets growth rate?
Other Long-Term Assets CAGR 5Y
0%
Over the last year, the Other Long-Term Assets growth was -8%. The average annual Other Long-Term Assets growth rates for Novan Inc have been -6% over the past three years .
